Searchable abstracts of presentations at key conferences in endocrinology

ea0041gp146 | Paediatric Endocrinology & Development | ECE2016

Breast development in male-to-female transgender patients after one year cross-sex hormonal treatment

de Blok Christel , Klaver Maartje , Nota Nienke , Dekker Marieke , den Heijer Martin

Background: In male to female transgender patients breast development is a key part in the process of feminization using cross sex hormone therapy. In the Endocrine Society’s clinical guideline ‘Endocrine treatment of transsexual persons’ the onset of breast growth is estimated as 3–6 months after starting cross sex hormone treatment. The maximum breast growth however is seen after 2–3 years. But how much growth, in centimeters or cup-sizes, we can exp...

ea0056oc3.5 | New insights in bone disorders | ECE2018

Change in bone mineral density during the first 10 years of gender affirming hormonal treatment in transwomen and transmen

Wiepjes Chantal , de Blok Christel , Vlot Mariska , de Jongh Renate , Lips Paul , den Heijer Martin

Background: Concerns about the effects of gender affirming hormonal treatment (HT) on bone mineral density (BMD) exists, particularly for transmen with decreasing estrogen levels. HT in transpersons affects BMD on short term, but long-term follow-up studies are lacking. Therefore this study aimed to investigate the change in BMD during the first 10 years of HT in adult transwomen and transmen, in order to determine whether it is necessary to assess BMD during HT.<p class="...

ea0056gp222 | Reproduction | ECE2018

Change in visceral fat and its relation with change in lipids in trans persons during hormonal therapy: results from a multicenter prospective study

Klaver Maartje , Wiepjes Chantal , de Blok Christel , Nota Nienke , Defreyne Justine , Schneider Thomas , Fisher Alessandra , T'Sjoen Guy , den Heijer Martin , de Mutsert Renee

Introduction: Excess visceral adipose tissue (VAT) is strongly related to multiple cardiovascular risk factors such as dyslipidemia. Hormonal therapy (HT) in trans persons affects total body fat and body fat distribution, but the effect on VAT and its relation to changes in lipids is unknown. The aim of our study was to investigate the effect of one year HT on changes in VAT and its relation with changes in total cholesterol, HDL, LDL, and triglycerides after one year of HT.</...

ea0056p955 | Female Reproduction | ECE2018

Breast cancer in transgender persons receiving gender affirming hormone treatment: results of a nationwide cohort study

JM de Blok Christel , Wiepjes Chantal M. , Nota Nienke M. , Engelen Klaartje van , Adank Muriel A. , Dreijerink Koen M.A. , Barbe Ellis , Konings Inge R.H.M. , den Heijer Martin

Background: Transpersons can receive gender affirming hormone therapy (HT) to induce physical changes. Little is known about the effect of HT on breast cancer (BC) risk.Objectives: To study the prevalence and characteristics of BC in transpersons with HT and to compare this prevalence with the general Dutch male and female population.Methods: Adult transpersons who were seen after 1991 and started HT in the VUmc were included. This...